Zyprexa drives Lilly's growth in Japan
This article was originally published in Scrip
Sales at Lilly's Japanese operation edged up by 2% to ¥91.8 billion ($936.7 million) last year, a solid increase for mainstay product Zyprexa (olanzapine) helping to offset some weakness elsewhere in the portfolio.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.